In Brief: Boehringer Mannheim Retavase
Executive Summary
Boehringer Mannheim Retavase: DuPont Merck will comarket the thrombolytic agent approved in October for acute myocardial infarction ("The Pink Sheet" Nov. 4, p. 5). The companies' combined sales force dedicated to Retavase will number over 400. Boehringer will donate 5% of Retavase sales to the development of a heart attack symptom awareness program that will be implemented in conjunction with the American Heart Association. The direct price to wholesalers for a Retavase kit will be $2,200...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth